Why Doximity Stock Plunged Today

Doximity reported mixed Q4 results, with sales up 5% and free cash flow up 11%, but earnings missed and shares fell 24% intraday. Management guided 2027 revenue growth to only 3% to 5% and said adjusted EBITDA margin will decline as AI product spending rises. AI adoption is improving, with nearly half of prescribers using AI tools and AI search/transcribe users tripling in nine months, but monetization has yet to meaningfully offset softer advertising demand.

Analysis

The market is pricing DOCS less as a durable compounder and more as a near-term earnings-quality story where incremental AI investment is being funded out of operating margin. That matters because the company’s network is already saturated; at this stage, upside is less about user growth and more about monetizing attention, so any slowdown in healthcare ad budgets hits operating leverage disproportionately. The combination of softer demand and heavier AI spend raises the probability of a multi-quarter margin reset rather than a one-off miss.

Second-order, the AI adoption data is more important than the reported quarter. If AI tools are spreading quickly inside the installed base, the near-term drag on EBITDA may be a deliberate land grab to lock in workflow dependency before monetization becomes obvious. That can support a better medium-term conversion rate, but only if usage translates into seat expansion or higher ARPU; otherwise DOCS risks building expensive product capability that mainly defends share rather than expands profit pools.

The selloff may also be overshooting on timing rather than on end-state value. A 12x forward multiple is cheap only if the growth floor stabilizes; if 2027 revenue settles in the mid-single digits and margins keep compressing, the stock can remain value-trapped for several quarters despite strong FCF generation. The key catalyst is not AI enthusiasm itself, but evidence that AI features improve retention or pricing power enough to offset the ad market slowdown within the next 2-3 reporting cycles.

Key Decisions for Investors

• Avoid adding long exposure to DOCS until the next 1-2 quarters show either stabilized EBITDA margins or clear AI-driven monetization; risk/reward is poor if the market re-rates it as a low-growth platform at 10-12x earnings.
• For investors already long DOCS, consider monetizing downside with a 3-6 month put spread financed against current holdings; the stock can stay weak while margin pressure and guidance skepticism persist, but the valuation limits outright collapse.
• Pair trade: long a higher-quality healthcare software name with clearer recurring monetization versus short DOCS over the next 1-2 quarters; DOCS is the cleaner short if the thesis is that AI spend is masking decelerating core demand.
• Set a catalyst watch on the next earnings print and customer commentary on AI suite expansion; if AI adoption converts into measurable pricing power or seat growth, DOCS could re-rate quickly given the compressed multiple.
• If looking for a tactical bounce, only trade DOCS long on post-earnings capitulation with a tight stop below the low of the reaction day; the thesis is mean reversion, not fundamental inflection.